Literature DB >> 32999882

Follow-Up Ileocolonoscopy Is Underused in Crohn's Disease Patients after Ileocecal Resection despite Higher Total and Inpatient Health-Care Costs Compared to Controls.

Stephan R Vavricka1,2, Thomas Greuter1,3, Beat Brüngger4, Eva Blozik4, Jennifer Celeiro5, Alain M Schoepfer6, Caroline Bähler4.   

Abstract

BACKGROUND: Postoperative recurrence is frequently observed after ileocecal resection in Crohn's disease (CD) patients. Since 2010, endoscopy within 1 year is considered the gold standard for its diagnosis. However, if and how frequent such endoscopies are performed in clinical practice remains unknown.
METHODS: We analyzed 1-year follow-up data on CD patients who underwent ileocecal resection between 2012 and 2014 and compared them with hospitalized, non-resected CD controls. Data were extracted from the Helsana database. Helsana is one of the largest Swiss health insurance companies providing coverage for 1.2 million individuals.
RESULTS: A total of 645 CD patients were identified with ≥1 hospitalization between 2012 and 2014 and a follow-up of 1 year. Of these, 79 (12.2%) underwent ileocecal resection. Although endoscopy rates increased over time and were higher in patients with resection versus controls (p = 0.029), in only 54.4% a 1-year follow-up ileocolonoscopy was performed. Postoperative prophylaxis with anti-tumor necrosis factor or azathioprine was prescribed in 63.3%. Female sex and age >60 years were independent predictors for not receiving prophylaxis (odds ratio [OR] 0.36, p = 0.048, and OR 0.2, p = 0.022). Patients with resection had significantly lower numbers of rehospitalizations (1.2 vs. 1.8, p = 0.021), with resection being an independent negative predictor for number of rehospitalizations in a Poisson regression model (incident risk ratio 0.64, p = 0.029). However, disease-related surgery was more often the cause for rehospitalization after resection versus controls (47.6 vs. 22.1%, p = 0.015). Total and inpatient health-care costs were higher in these patients.
CONCLUSION: Endoscopies are underused after ileocecal resection. This contrasts current guidelines. Physicians should be aware of this underuse and perform follow-up examinations more often.
Copyright © 2020 by S. Karger AG, Basel.

Entities:  

Keywords:  Crohn's disease; Follow-up; Ileocecal resection; Postoperative recurrence

Year:  2020        PMID: 32999882      PMCID: PMC7506201          DOI: 10.1159/000507115

Source DB:  PubMed          Journal:  Inflamm Intest Dis        ISSN: 2296-9365


  32 in total

1.  Long-term clinical results of ileocecal resection for Crohn's disease.

Authors:  Garret Cullen; Aoibhlinn O'toole; Denise Keegan; Kieran Sheahan; John M Hyland; Diarmuid P O'donoghue
Journal:  Inflamm Bowel Dis       Date:  2007-11       Impact factor: 5.325

2.  Surgery for Crohn's disease: look harder, act faster.

Authors:  Ashwin N Ananthakrishnan
Journal:  Lancet       Date:  2014-12-24       Impact factor: 79.321

3.  Fecal calprotectin for evaluating postoperative recurrence of Crohn's disease: a meta-analysis of prospective studies.

Authors:  Yun Qiu; Ren Mao; Bai-li Chen; Yao He; Zhi-rong Zeng; Ling Xue; Xin-ming Song; Zi-ping Li; Min-hu Chen
Journal:  Inflamm Bowel Dis       Date:  2015-02       Impact factor: 5.325

Review 4.  The surgical intervention: earlier or never?

Authors:  W A Bemelman; M Allez
Journal:  Best Pract Res Clin Gastroenterol       Date:  2014-05-10       Impact factor: 3.043

5.  Infliximab, azathioprine, or combination therapy for Crohn's disease.

Authors:  Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

6.  Crohn's disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection.

Authors:  Miguel Regueiro; Kevin E Kip; Wolfgang Schraut; Leonard Baidoo; Antonia R Sepulveda; Marilyn Pesci; Sandra El-Hachem; Janet Harrison; David Binion
Journal:  Inflamm Bowel Dis       Date:  2011-01       Impact factor: 5.325

7.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

8.  Crohn's disease management after intestinal resection: a randomised trial.

Authors:  Peter De Cruz; Michael A Kamm; Amy L Hamilton; Kathryn J Ritchie; Efrosinia O Krejany; Alexandra Gorelik; Danny Liew; Lani Prideaux; Ian C Lawrance; Jane M Andrews; Peter A Bampton; Peter R Gibson; Miles Sparrow; Rupert W Leong; Timothy H Florin; Richard B Gearry; Graham Radford-Smith; Finlay A Macrae; Henry Debinski; Warwick Selby; Ian Kronborg; Michael J Johnston; Rodney Woods; P Ross Elliott; Sally J Bell; Steven J Brown; William R Connell; Paul V Desmond
Journal:  Lancet       Date:  2014-12-24       Impact factor: 79.321

9.  Vedolizumab as induction and maintenance therapy for Crohn's disease.

Authors:  William J Sandborn; Brian G Feagan; Paul Rutgeerts; Stephen Hanauer; Jean-Frédéric Colombel; Bruce E Sands; Milan Lukas; Richard N Fedorak; Scott Lee; Brian Bressler; Irving Fox; Maria Rosario; Serap Sankoh; Jing Xu; Kristin Stephens; Catherine Milch; Asit Parikh
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

10.  Recurrence after surgery in Crohn's disease. Relationship to location of disease (clinical pattern) and surgical indication.

Authors:  G Whelan; R G Farmer; V W Fazio; M Goormastic
Journal:  Gastroenterology       Date:  1985-06       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.